General Certificate of Education (A-level) June 2013

Biology

BIOL1

(Specification 2410)

Unit 1: Biology and Disease

Final



Mark schemes are prepared by the Principal Examiner and considered, together with the relevant questions, by a panel of subject teachers. This mark scheme includes any amendments made at the standardisation events which all examiners participate in and is the scheme which was used by them in this examination. The standardisation process ensures that the mark scheme covers the students' responses to questions and that every examiner understands and applies it in the same correct way. As preparation for standardisation each examiner analyses a number of students' scripts: alternative answers not already covered by the mark scheme are discussed and legislated for. If, after the standardisation process, examiners encounter unusual answers which have not been raised they are required to refer these to the Principal Examiner.

It must be stressed that a mark scheme is a working document, in many cases further developed and expanded on the basis of students' reactions to a particular paper. Assumptions about future mark schemes on the basis of one year's document should be avoided; whilst the guiding principles of assessment remain constant, details will change, depending on the content of a particular examination paper.

Further copies of this Mark Scheme are available from: aqa.org.uk

Copyright © 2013 AQA and its licensors. All rights reserved.

Copyright

AQA retains the copyright on all its publications. However, registered schools/colleges for AQA are permitted to copy material from this booklet for their own internal use, with the following important exception: AQA cannot give permission to schools/colleges to photocopy any material that is acknowledged to a third party even for internal use within the school/college.

Set and published by the Assessment and Qualifications Alliance.

The Assessment and Qualifications Alliance (AQA) is a company limited by guarantee registered in England and Wales (company number 3644723) and a registered charity (registered charity number 1073334). Registered address: AQA, Devas Street, Manchester M15 6EX.

| Question | tion Marking Guidelines | | Comments |
|----------|--|---|--|
| 1(a) | 1. A : phospholipid (layer); | 2 | Reject hydrophobic / hydrophilic phospholipid |
| | B: pore/channel/pump/carrier/ transmembrane/intrinsic/transport protein; | | Ignore unqualified reference to protein |
| 1(b)(i) | Condensation (reaction); | 1 | |
| 1(b)(ii) | | | Function must be for organelle named Incorrect organelle = 0 1. Accept smooth endoplasmic reticulum 3. Accept alternative correct functions of rough endoplasmic reticulum. ER/RER is insufficient 3. Accept folding polypeptide/protein 6. Reject produce/make energy 6. Accept produce energy in the form of ATP |

| Question | Marking Guidelines | Marks | Comments |
|----------|---|-------|---|
| 2(a) | 1. (Enzyme has) <u>active site;</u> | 2 | Reject active site is same shape as substrate |
| | | | Reject active site is on the substrate |
| | 2. Only substrate fits (the active site); | | Accept active site forms during induced fit |
| | | | 2. Accept converse statement |
| 2(b) | | 3 | Assume "it" = allopurinol |
| | 1. (Allopurinol) is a similar shape to xanthine; | | Reject <u>same</u> shape. Accept similar structure |
| | 2. (Allopurinol) enters active site / is a | | 2. Ignore e-s complexes in relation to inhibitor |
| | competitive inhibitor; | | Reject non-competitive inhibitor in the context of binding to the active site |
| | Less xanthine binds/fewer e-s | | 2. Ignore complementary/fits |
| | complexes/fewer uric acid crystals formed/less uric acid formed; | | 3. Reject <u>no</u> e-s complexes/xanthine <u>cannot</u> enter active site, <u>no</u> uric acid |
| | | | Can award in context of non-competitive inhibition |

| Question | Marking Guidelines | Marks | Comments | |
|----------|--|-------|--|--|
| 3(a)(i) | (Simple) diffusion; | 1 | Reject facilitated diffusion Accept lipid diffusion | |
| 3(a)(ii) | Thin walls/cells; (Total) surface area is large; | 2 | 'Short diffusion pathway' alone is an explanation not a description Accept squamous epithelia / one cell thick Ignore references to tacking action | |
| | | | 'volume ratio' | |
| 3(b) | Loss of elasticity/elastic tissue; Scar tissue; Less recoil; | 2 max | 1. Accept elastin | |

| Question | Marking Guidelines | Marks | Comments |
|----------|--|-------|--|
| 4(a) | Toxin (produced by bacterium) causes (chloride) ions to move into (lumen of) intestine; <u>Water potential</u> (of intestine contents) falls / water moves by <u>osmosis</u> into intestine/out of cells; | 2 | Reject incorrect ion Direction of ion movement must be clear Ignore movement of water from blood (rather than cells) |
| 4(b) | Both show little/no increase/remain constant in January/February; (Up to May) sea temperature rises more quickly/before increase in cholera; Both reach a peak in/decline after April/May; | 2 max | Ignore references to correlation Accept May to June |
| 4(c) | Positive correlation from January to September/October (between sea temperature and cholera cases); Only records people in hospital with cholera / may be people with cholera not in hospital; Negative correlation/cases rising as sea temperature falls in October/November; | 2 max | Ignore as sea temperature rises, cholera cases rise, as in stem Accept any two months within range 'At end of year' insufficient |

| 4(d) | Suitable suggestion with explanation;; 1. Have produced memory cells; 2. After previous infection/vaccination; OR 3. Different forms of cholera; 4. Some don't produce much/any toxins; OR 5. Few bacteria ingested; 6. Not enough toxin to produce symptoms; | 2 | 'Have become immune' is not enough Accept 'produces secondary response' Accept types /strains /variety |
|------|---|---|--|
| | OR 7. Some people naturally resistant to bacterium; 8. Because of structure of cell membranes / amount of secretions eg bile/pancreatic juices; | | |

| Question | Marking Guidelines | Marks | Comments |
|----------|--|-------|---|
| 5(a) | To allow comparison; Because different number of cells in samples / different times for incubation / numbers become easier to manipulate; | 2 | |
| 5(b) | 203.7(%);; | 2 | Allow 1 mark for 21.8/10.7 Allow 1 mark for correct answer (203.74) but not correctly to 1 dp 204= 1 mark |
| 5(c)(i) | (At every concentration) uptake is faster at 37°C/at higher temperature; Due to faster respiration/ATP production; | 2 | |
| 5(c)(ii) | Uptake at 37°C only small increase /levelling off/almost constant; As carrier proteins full; Concentration of imatinib is not the limiting factor; | 2 max | Accept 'no (significant) change' Ignore use of numbers |

| Question | Marking Guidelines | Marks | Comments | | |
|----------|--|-------|--|--|--|
| 6(a) | Add iodine/potassium iodide solution to the food sample; Blue/black/purple indicates starch is present; | 2 | Allow 'iodine' Must be in the context of the correct reagent | | |
| 6(b) | Starch digested to maltose/by amylase; Maltose digested to glucose/by maltase; Digestion of sucrose is a single step/only one enzyme/sucrase; | 3 | Ignore 'hard to digest/easily digested' 3. Accept converse for starch 3. Do not accept digestion of sucrose is faster | | |
| 6(c) | Smoking increases risk of CHD; Introduces another variable; | 1 max | | | |
| 6(d)(i) | No effect on risk with diet group 1 and 2/lowest glycaemic load; Above diet group 2/in higher groups, risk increases as glycaemic load increases; | 1 max | Simple statement of correlation is not enough for this mark | | |
| 6(d)(ii) | For diet group 2 and above, increase in risk of CHD as GL increases; (Higher GL diets lead to) more (harmful) lipids (in blood), so greater risk of atheroma; Atheroma leads to blockage of <u>coronary artery</u> / increased risk of blood clot in <u>coronary artery</u>; | 2 max | Ignore reference to lipids in diet Ignore references to myocardial infarction/heart attack | | |

| Question | Marking Guidelines | Marks | Comments |
|----------|---|-------|---|
| 7(a) | Microvilli; Carrier proteins/co-transport proteins/membrane-bound enzymes; | | 1. Accept large surface area |
| | 3. Many mitochondria; | | Accept lots of ATP produced |
| 7(b)(i) | Substance that causes an immune response/production of antibodies; | 1 | Ignore foreign/non-self |
| 7(b)(ii) | Not lipid soluble; Too large (to diffuse through the membrane); Antigens do not have the complementary shape/cannot bind to receptor/channel/carrier proteins (in membranes of other epithelial cells); | 2 max | |
| 7(c) | (Vaccine contains) antigen/attenuated/dead pathogen; Microfold cells take up/bind and present/transport antigen (to immune system/lymphocytes/T- cells); T-cells activate B-cells; B-cells divide/form clone/undergo mitosis; B-cells produce antibodies; Memory cells produced; More antibodies/antibodies produced faster in secondary response/on reinfection; | 5 max | Reject if in context of injection of vaccine Accept T-cells release cytokines Accept plasma cells for B-cells Ignore T/B in reference to memory cells Must be comparative |

| Question | Marking Gu | idelines | Marks | Comments | |
|----------|-----------------------|---|-------|--|--|
| 8(a) | activity | nds wave of electrical / impulses (across atria) atrial contraction; | 5 | Accept excitation | |
| | immedi ventricl | nducting tissue prevents ate contraction of es/prevents impulses g the ventricles; | | | |
| | | lays (impulse) whilst blood atria/ventricles fill; | | | |
| | | sends wave of electrical / impulses down Bundle of | | 4. Allow Purkyne fibres/tissue | |
| | 5. Causing base up | g ventricles to contract from o; | | | |
| 8(b) | | has higher pressure than e (due to filling/contraction); | 5 max | Start anywhere in sequence, but events must be in the correct order. | |
| | 2. Atriover | ntricular valve opens; | | Accept bicuspid, reject tricuspid | |
| | | e has higher pressure than due to filling/contraction); | | Allow: blood passes through the valve = valve open / blood stopped | |
| | | ntricular valve closes; | | from passing through the valve = valve closed | |
| | 5. Ventricl aorta; | e has higher pressure than | | 'prevents backflow' is not enough | |
| | | | | Points 1, 3, 5, and 7 must be comparative: eg high <u>er</u> | |
| | 6. Semilur | nar valve opens; | | 6. Allow aortic valve | |
| | • | pressure in aorta than e (as heart relaxes); | | Marks 2, 4, 6, 8 given in the correct sequence can gain 4 marks | |
| | | nar valve closes; | | 8. Allow aortic valve | |
| | | | | 'prevents backflow' is not enough | |
| | | e/atrial/ventricular) <u>on</u> causes increase in :; | | | |